{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:41:09Z","timestamp":1787020869132,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000324","name":"Gatsby Charitable Foundation","doi-asserted-by":"publisher","award":["GAT 3676"],"award-info":[{"award-number":["GAT 3676"]}],"id":[{"id":"10.13039\/501100000324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bladder symptoms are common in Parkinson\u2019s disease (PD), affecting half of all individuals. These have significant impact on quality of life as well as implications for morbidity, contributing to falls and hospital admission. The treatment of bladder symptoms can be complicated by the tendency to side-effects in people with PD including cognitive impairment and gait instability with anti-muscarinics. The development of new, better treatments is therefore warranted. Tibial nerve stimulation is a form of neuromodulation demonstrated to improve overactive bladder symptoms in non-neurogenic cohorts. Previously requiring hospital attendance, we aim to explore the use of this intervention using a simple device that can be used by patients at home.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>STRIPE is a phase II randomised control trial of tibial nerve stimulation delivered by the Geko\u2122 device, a small, self-adhesive neuromuscular stimulation device currently used for thromboembolism prophylaxis post-surgery. Active tibial nerve stimulation will be compared to sham stimulation, with participants blinded to treatment allocation and undertaking outcome assessment whilst still blinded. Participants will be asked to self-administer stimulation at home twice per week, for 30\u00a0min per session, over the course of 3\u00a0months. Primary outcome measure will be the International Consultation on Incontinence Overactive Bladder Questionnaire (OAB) at week 12. Secondary outcomes will include pre- and post-intervention bladder diary (frequency, urgency episodes, nocturia), patient perception of global change, bowel function and bladder-related quality of life. Participants will be recruited from the Proactive Integrated Management and Empowerment (PRIME) cross-sectional trial in which participants have been screened for bladder symptoms and invited to take part, as well as clinician referral from around the region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This trial will involve a randomised control trial of a novel and easy to use method of delivering tibial nerve stimulation for PD in the patient\u2019s own home. This may potentially have huge benefit, avoiding the problems with side effects that can be seen with anti-muscarinics and providing a new potential modality of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ISRCTN11484954. Registered on 22 June 2021.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-022-06827-3","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T18:02:31Z","timestamp":1666980151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Stimulation of the Tibial nerve Repetitively to Improve Incontinence in Parkinson\u2019s Electronically (STRIPE trial): a randomised control trial of tibial nerve stimulation for bladder symptoms in Parkinson\u2019s disease using a self-contained wearable device"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4685-375X","authenticated-orcid":false,"given":"Matthew D.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Tenison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus J.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoav","family":"Ben-Shlomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily J.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"6827_CR1","unstructured":"Parkinson\u2019s UK. Incidence and prevalence of Parkinson\u2019s in the UK: results from the clinical practice datalink summary report. Published online 2018."},{"issue":"11","key":"6827_CR2","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/mds.22643","volume":"24","author":"P Barone","year":"2009","unstructured":"Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson\u2019s disease. Mov Disord. 2009;24(11):1641\u20139. https:\/\/doi.org\/10.1002\/mds.22643.","journal-title":"Mov Disord"},{"issue":"1\u20132","key":"6827_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1566-0702(01)00295-8","volume":"92","author":"R Sakakibara","year":"2001","unstructured":"Sakakibara R, Shinotoh H, Uchiyama T, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson\u2019s disease. Auton Neurosci Basic Clin. 2001;92(1\u20132):76\u201385. https:\/\/doi.org\/10.1016\/S1566-0702(01)00295-8.","journal-title":"Auton Neurosci Basic Clin"},{"issue":"12","key":"6827_CR4","doi-asserted-by":"publisher","first-page":"e006434","DOI":"10.1136\/bmjopen-2014-006434","volume":"4","author":"KHO Deane","year":"2015","unstructured":"Deane KHO, Flaherty H, Daley DJ, et al. Priority setting partnership to identify the top 10 research priorities for the management of parkinson\u2019s disease. BMJ Open. 2015;4(12):e006434. https:\/\/doi.org\/10.1136\/bmjopen-2014-006434.","journal-title":"BMJ Open."},{"issue":"5","key":"6827_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.parkreldis.2015.01.017","volume":"21","author":"V Low","year":"2015","unstructured":"Low V, Ben-Shlomo Y, Coward E, Fletcher S, Walker R, Clarke CE. Measuring the burden and mortality of hospitalisation in Parkinson\u2019s disease: a cross-sectional analysis of the English Hospital Episodes Statistics database 2009\u20132013. Park Relat Disord. 2015;21(5):449\u201354. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.01.017.","journal-title":"Park Relat Disord"},{"key":"6827_CR6","doi-asserted-by":"crossref","unstructured":"Appell A. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology. Dec;50(6A Suppl):90-6; discussion 97-9.","DOI":"10.1016\/S0090-4295(97)00599-2"},{"issue":"2","key":"6827_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","volume":"63","author":"V Khullar","year":"2013","unstructured":"Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283\u201395. https:\/\/doi.org\/10.1016\/j.eururo.2012.10.016.","journal-title":"Eur Urol"},{"issue":"4","key":"6827_CR8","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.juro.2009.12.036","volume":"183","author":"KM Peters","year":"2010","unstructured":"Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183(4):1438\u201343. https:\/\/doi.org\/10.1016\/j.juro.2009.12.036.","journal-title":"J Urol"},{"issue":"1","key":"6827_CR9","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.juro.2011.04.023.Irritation","volume":"186","author":"C Tai","year":"2011","unstructured":"Tai C, Chen M, Shen B, Wang J, Roppolo JR, de Groat WC. Irritation induced bladder overactivity is suppressed by tibial nerve stimulation in cats. J Urol. 2011;186(1):326\u201330. https:\/\/doi.org\/10.1016\/j.juro.2011.04.023.Irritation.","journal-title":"J Urol"},{"issue":"4","key":"6827_CR10","first-page":"3","volume":"2006","author":"G Krivoborodov","year":"2006","unstructured":"Krivoborodov G, Gekht A, Korshunova E. Tibial neuromodulation in the treatment of neurogenic detrusor hyperactivity in patients with Parkinson\u2019s disease. Urologiia. 2006;2006(4):3\u20136.","journal-title":"Urologiia"},{"issue":"1","key":"6827_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/nau.20593","volume":"28","author":"S Canbaz Kabay","year":"2009","unstructured":"Canbaz Kabay S, Kabay S, Yucel M, Ozden H. Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson\u2019s disease. Neurourol Urodyn. 2009;28(1):62\u20137.","journal-title":"Neurourol Urodyn"},{"key":"6827_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.urology.2015.09.026","volume":"87","author":"S Kabay","year":"2016","unstructured":"Kabay S, Canbaz Kabay S, Cetiner M, et al. The clinical and urodynamic results of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson\u2019s disease. Urology. 2016;87:76\u201381. https:\/\/doi.org\/10.1016\/j.urology.2015.09.026.","journal-title":"Urology"},{"issue":"1","key":"6827_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/nau.23843","volume":"38","author":"I Ram\u00edrez-Garc\u00eda","year":"2019","unstructured":"Ram\u00edrez-Garc\u00eda I, Blanco-Ratto L, Kauffmann S, Carralero-Mart\u00ednez A, S\u00e1nchez E. Efficacy of transcutaneous stimulation of the posterior tibial nerve compared to percutaneous stimulation in idiopathic overactive bladder syndrome: randomized control trial. Neurourol Urodyn. 2019;38(1):261\u20138. https:\/\/doi.org\/10.1002\/nau.23843.","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"6827_CR14","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/nau","volume":"30","author":"M de Seze","year":"2011","unstructured":"de Seze M, Raibaut P, Gallien P, et al. Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn. 2011;30(3):306\u201311. https:\/\/doi.org\/10.1002\/nau.","journal-title":"Neurourol Urodyn"},{"issue":"11","key":"6827_CR15","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.purol.2013.07.004","volume":"23","author":"A Ohannessian","year":"2013","unstructured":"Ohannessian A, Kabor\u00e9 FA, Agostini A, et al. Transcutaneous tibial nerve stimulation in the overactive bladder syndrome in patients with Parkinson\u2019s syndromes. Prog en Urol. 2013;23(11):936\u20139. https:\/\/doi.org\/10.1016\/j.purol.2013.07.004.","journal-title":"Prog en Urol"},{"issue":"7","key":"6827_CR16","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.purol.2019.02.006","volume":"29","author":"L Charvolin","year":"2019","unstructured":"Charvolin L, Guinet-Lacoste A, Waz D, Godmer M, Rode G. Results and compliance of transcutaneous tibial nerve stimulation on overactive bladder syndrome in patients with Parkinson\u2019s disease. Retrospective Study. Prog en Urol. 2019;29(7):378\u201384. https:\/\/doi.org\/10.1016\/j.purol.2019.02.006.","journal-title":"Prog en Urol"},{"issue":"1","key":"6827_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/WON.0000000000000078","volume":"42","author":"MC Perissinotto","year":"2015","unstructured":"Perissinotto MC, D\u2019ancona CAL, Lucio A, Campos RM, Abreu A. Transcutaneous tibial nerve stimulation in the treatment of lower urinary tract symptoms and its impact on health-related quality of life in patients with parkinson disease: a randomized controlled trial. J Wound Ostomy Cont Nurs. 2015;42(1):94\u20139. https:\/\/doi.org\/10.1097\/WON.0000000000000078.","journal-title":"J Wound Ostomy Cont Nurs"},{"issue":"6","key":"6827_CR18","doi-asserted-by":"publisher","first-page":"912","DOI":"10.21037\/tau.2018.09.12","volume":"7","author":"JH Seth","year":"2018","unstructured":"Seth JH, Gonzales G, Haslam C, et al. Feasibility of using a novel non-invasive ambulatory tibial nerve stimulation device for the home-based treatment of overactive bladder symptoms. Transl Androl Urol. 2018;7(6):912\u20139. https:\/\/doi.org\/10.21037\/tau.2018.09.12.","journal-title":"Transl Androl Urol"},{"key":"6827_CR19","unstructured":"National Institute for Clinical Excellence. The geko device for reducing the risk of venous thromboembolism. Medical Technologies Guidance [IMTG19]."},{"issue":"1","key":"6827_CR20","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/nau.24595","volume":"40","author":"TG Araujo","year":"2021","unstructured":"Araujo TG, Schmidt AP, Sanches PRS, Silva Junior DP, Rieder CRM, Ramos JGL. Transcutaneous tibial nerve home stimulation for overactive bladder in women with Parkinson\u2019s disease: a randomized clinical trial. Neurourol Urodyn. 2021;40(1):538\u201348. https:\/\/doi.org\/10.1002\/nau.24595.","journal-title":"Neurourol Urodyn"},{"issue":"15","key":"6827_CR21","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-Sponsored Revision of the Unified Parkinson \u2019 s Disease Rating Scale ( MDS-UPDRS ): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129\u201370. https:\/\/doi.org\/10.1002\/mds.22340.","journal-title":"Mov Disord"},{"key":"6827_CR22","unstructured":"Verghese T, Tryposkiadis K, Arifeen K, Middelton L, Latthe P. Minimal clinically important difference (MCID) for the International Consultation on Incontinence Questionnaire-Overactive Bladder (ICIQ- OAB). International Continence Society meeting. 2017."},{"issue":"5","key":"6827_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/mdc3.12636","volume":"5","author":"A Pavy-Le Traon","year":"2018","unstructured":"Pavy-Le Traon A, Cotterill N, Amarenco G, et al. Clinical rating scales for urinary symptoms in Parkinson disease: critique and recommendations. Mov Disord Clin Pract. 2018;5(5):479\u201391.","journal-title":"Mov Disord Clin Pract"},{"key":"6827_CR24","doi-asserted-by":"publisher","unstructured":"Brookes ST, Donovan JL, Wright M, Jackson S, Abrams P. A scored form of the Bristol Female Lower Urinary Tract Symptoms questionnaire: data from a randomized controlled trial of surgery for women with stress incontinence. Published online 2004https:\/\/doi.org\/10.1016\/j.ajog.2003.12.027","DOI":"10.1016\/j.ajog.2003.12.027"},{"key":"6827_CR25","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1023\/A:1016370925601","volume":"11","author":"K Coyne","year":"2002","unstructured":"Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire\u00a0: The OAB-q. Qual Life Res. 2002;11:563\u201374 (Published online).","journal-title":"Qual Life Res"},{"key":"6827_CR26","doi-asserted-by":"publisher","unstructured":"Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. 46202:606\u2013613score. Published online 2006:625\u2013631. https:\/\/doi.org\/10.1038\/sj.sc.3101887","DOI":"10.1038\/sj.sc.3101887"},{"issue":"6","key":"6827_CR27","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0022-5347(05)66926-1","volume":"164","author":"J Donovan","year":"2000","unstructured":"Donovan J, Peters T, Abrams P, Brooks S, de la Rosette J, Schafer W. Scoring the short form ICSmale SF questionnaire. J Urol. 2000;164(6):1948\u201355.","journal-title":"J Urol"},{"issue":"11","key":"6827_CR28","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/mds.20153","volume":"19","author":"M Visser","year":"2004","unstructured":"Visser M, Marinus J, Stiggelbout AM. Assessment of autonomic dysfunction in Parkinson\u2019s disease: the SCOPA-AUT. Mov Disord. 2004;19(11):1306\u201312. https:\/\/doi.org\/10.1002\/mds.20153.","journal-title":"Mov Disord"},{"key":"6827_CR29","doi-asserted-by":"crossref","unstructured":"Krogh K, Christensen P, Sabroe S, Laurberg S. Neurogenic bowel dysfunction score. Spinal Cord. 2006;44(10):625-31.","DOI":"10.1038\/sj.sc.3101887"},{"issue":"7","key":"6827_CR30","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1111\/ejn.12307","volume":"38","author":"NJ Davis","year":"2013","unstructured":"Davis NJ, Gold E, Pascual-Leone A, Bracewell RM. Challenges of proper placebo control for non-invasive brain stimulation in clinical and experimental applications. Eur J Neurosci. 2013;38(7):2973\u20137. https:\/\/doi.org\/10.1111\/ejn.12307.","journal-title":"Eur J Neurosci"},{"key":"6827_CR31","doi-asserted-by":"publisher","unstructured":"Li S, Li X, Theisen K, et al. Saphenous nerve stimulation normalizes bladder underactivity induced by tibial nerve stimulation in cats. Published online 2021:3\u20134. https:\/\/doi.org\/10.1152\/ajprenal.00422.2017","DOI":"10.1152\/ajprenal.00422.2017"},{"key":"6827_CR32","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.wneu.2016.02.108","volume":"90","author":"L Li","year":"2016","unstructured":"Li L, Leung GK, Lui W. Sacral nerve stimulation for neurogenic bladder. World Neurosurg. 2016;90:236\u201343. https:\/\/doi.org\/10.1016\/j.wneu.2016.02.108.","journal-title":"World Neurosurg"},{"key":"6827_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2021.01.044","author":"S Kabay","year":"2021","unstructured":"Kabay S, Kabay S. The sustained therapeutic effects of percutaneous posterior tibial nerve stimulation in the treatment of neurogenic lower urinary tract symptoms in patients with Parkinson\u2019s disease: 24-months clinical and urodynamic results. Urology. 2021. https:\/\/doi.org\/10.1016\/j.urology.2021.01.044 (Published online).","journal-title":"Urology"},{"issue":"6","key":"6827_CR34","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1097\/01.ju.0000067446.17576.bd","volume":"169","author":"G Amarenco","year":"2003","unstructured":"Amarenco G, Sheikh Ismael S, Even-Schneider A, et al. Urodynamic effect of acute transcutaneous posterior tibial nerve stimulation in overactive bladder. J Urol. 2003;169(6):2210\u20135. https:\/\/doi.org\/10.1097\/01.ju.0000067446.17576.bd.","journal-title":"J Urol"},{"issue":"2","key":"6827_CR35","doi-asserted-by":"publisher","first-page":"R428","DOI":"10.1152\/AJPREGU.00277.2019","volume":"318","author":"S Li","year":"2020","unstructured":"Li S, Browning J, Theisen K, et al. Prolonged nonobstructive urinary retention induced by tibial nerve stimulation in cats. Am J Physiol Regul Integr Comp Physiol. 2020;318(2):R428\u201334. https:\/\/doi.org\/10.1152\/AJPREGU.00277.2019.","journal-title":"Am J Physiol Regul Integr Comp Physiol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06827-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06827-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06827-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T18:02:36Z","timestamp":1666980156000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06827-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6827"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06827-3","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]},"assertion":[{"value":"9 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was given ethical approval by the Camden and Kings Cross research ethics committee (Ref. 21\/LO\/0418). The trial has also been approved by the Research Governance department of University of Bristol.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate\u00a0{24}"}},{"value":"Consent for inclusion of content from the qualitative sub-study is integrated into the STRIPE consent form. Phrasing and excerpts included in the published analysis are anticipated to be too general and broad for individuals to be specifically identified by others. No images or video material will be collected.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"This study is entirely independent from the manufacturer of Geko\u2122 and is not endorsed or financially supported by them. Devices will be purchased at the market rate from a medical wholesaler.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"912"}}